JP2014528700A5 - - Google Patents

Download PDF

Info

Publication number
JP2014528700A5
JP2014528700A5 JP2014521695A JP2014521695A JP2014528700A5 JP 2014528700 A5 JP2014528700 A5 JP 2014528700A5 JP 2014521695 A JP2014521695 A JP 2014521695A JP 2014521695 A JP2014521695 A JP 2014521695A JP 2014528700 A5 JP2014528700 A5 JP 2014528700A5
Authority
JP
Japan
Prior art keywords
inhibitor
composition
composition according
seq
stranded rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014521695A
Other languages
English (en)
Japanese (ja)
Other versions
JP6313203B2 (ja
JP2014528700A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/046928 external-priority patent/WO2013012806A2/en
Publication of JP2014528700A publication Critical patent/JP2014528700A/ja
Publication of JP2014528700A5 publication Critical patent/JP2014528700A5/ja
Application granted granted Critical
Publication of JP6313203B2 publication Critical patent/JP6313203B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014521695A 2011-07-18 2012-07-16 Ａｌｕ−ｒｎａ誘導変性からの細胞の保護及び細胞保護用阻害剤 Active JP6313203B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161508867P 2011-07-18 2011-07-18
US61/508,867 2011-07-18
US201161543038P 2011-10-04 2011-10-04
US61/543,038 2011-10-04
PCT/US2012/046928 WO2013012806A2 (en) 2011-07-18 2012-07-16 Protection of cells from alu-rna-induced degenereation and inhibitors for protecting cells

Publications (3)

Publication Number Publication Date
JP2014528700A JP2014528700A (ja) 2014-10-30
JP2014528700A5 true JP2014528700A5 (enExample) 2015-08-20
JP6313203B2 JP6313203B2 (ja) 2018-04-18

Family

ID=47558691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014521695A Active JP6313203B2 (ja) 2011-07-18 2012-07-16 Ａｌｕ−ｒｎａ誘導変性からの細胞の保護及び細胞保護用阻害剤

Country Status (9)

Country Link
US (1) US9453226B2 (enExample)
EP (2) EP3366302B1 (enExample)
JP (1) JP6313203B2 (enExample)
CN (1) CN103889461B (enExample)
AU (1) AU2012284223B2 (enExample)
CA (2) CA3205596A1 (enExample)
ES (1) ES2907620T3 (enExample)
PT (1) PT3366302T (enExample)
WO (1) WO2013012806A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138555A2 (en) 2009-05-26 2010-12-02 University Of Florida Research Foundation, Inc. Small peptide expression system in mammalian cells
EP2631291B1 (en) 2010-10-22 2019-05-15 OliX Pharmaceuticals, Inc. Nucleic acid molecules inducing rna interference, and uses thereof
US9707235B1 (en) 2012-01-13 2017-07-18 University Of Kentucky Research Foundation Protection of cells from degeneration and treatment of geographic atrophy
EP2847215A1 (en) * 2012-05-07 2015-03-18 Synthes GmbH Methods and devices for treating intervertebral disc disease
DK2853597T3 (en) 2012-05-22 2019-04-08 Olix Pharmaceuticals Inc RNA INTERFERENCE-INducing NUCLEIC ACID MOLECULES WITH CELL PENETENING EQUIPMENT AND USE THEREOF
WO2014039696A2 (en) 2012-09-05 2014-03-13 Cold Spring Harbor Laboratory Transposable elements, tdp-43, and neurodegenerative disorders
AU2014249045A1 (en) 2013-03-11 2015-10-29 University Of Florida Research Foundation, Inc. Delivery of CARD protein as therapy for occular inflammation
US9326983B2 (en) 2013-08-01 2016-05-03 University Of Kentucky Research Foundation Compositions and methods for treating retinal degradation
WO2015095609A1 (en) * 2013-12-19 2015-06-25 The J. David Gladstone Institute Inhibition of interferon-gamma-inducible protein 16 (ifi16)
EP3107939B1 (en) 2014-02-19 2020-06-17 University of Florida Research Foundation, Inc. Delivery of nrf2 as therapy for protection against reactive oxygen species
WO2015138628A1 (en) * 2014-03-11 2015-09-17 University Of Florida Research Foundation, Inc. Use of aav-expressed m013 protein as an anti-inflammatory therapeutic
EP3177732A4 (en) * 2014-08-08 2018-04-25 ModernaTX, Inc. Compositions and methods for the treatment of ophthalmic diseases and conditions
DK3261644T3 (da) 2015-02-26 2021-06-28 Univ Kentucky Res Found Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning
US11219623B2 (en) 2015-02-26 2022-01-11 University Of Kentucky Research Foundation Inflammasome inhibition for the treatment of Parkinson's disease, Alzheimer's disease and multiple sclerosis
JP7085712B2 (ja) * 2015-09-03 2022-06-17 ビー．ジー． ネゲヴ テクノロジーズ アンド アプリケーションズ リミテッド、アット ベン－グリオン ユニヴァーシティ Ｖｄａｃ１由来ペプチドの類似体
EP3373939A4 (en) * 2015-11-10 2019-06-26 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University MEDIUM AND METHOD FOR REDUCING TUMORIGENITY OF CANCER STEM CELLS
EP3377630A4 (en) * 2015-11-16 2020-01-01 Olix Pharmaceuticals, Inc. Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3
JP6944942B2 (ja) 2016-02-02 2021-10-06 オリックス ファーマシューティカルズ，インコーポレーテッド ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療
CN109415413A (zh) * 2016-06-07 2019-03-01 耶路撒冷希伯来大学伊森姆研究发展有限公司 髓样分化因子88(myd88)的主链环化抑制肽
WO2017214553A1 (en) * 2016-06-09 2017-12-14 The General Hospital Corporation Modulating the cellular stress response
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
WO2018039371A1 (en) * 2016-08-26 2018-03-01 The Regents Of The University Of California Compositions and methods for inhibiting stem cell aging
CN110545835A (zh) 2016-12-23 2019-12-06 A·勒布朗 Caspase-1抑制及其用于预防和治疗神经病症的用途
EP3580339A4 (en) 2017-02-10 2020-12-23 Research & Business Foundation Sungkyunkwan University LONG DOUBLE STRAND RNA FOR RNA INTERFERENCE
GB2561540A (en) 2017-03-13 2018-10-24 Nodthera Ltd Chemical compounds
EP3607063A4 (en) * 2017-04-03 2021-01-13 Duke University COMPOSITIONS AND METHODS FOR DIFFERENTIAL INDUCTION OF CELLULAR DEATH AND INTERFERON EXPRESSION
EP3672579A4 (en) * 2017-10-10 2021-06-23 University of Virginia Patent Foundation COMPOSITIONS AND METHODS OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND GEOGRAPHICAL ATROPHY
JP7565802B2 (ja) * 2018-06-27 2024-10-11 ザ チルドレンズ メディカル センター コーポレーション 炎症抑制用化合物
KR102138256B1 (ko) * 2018-09-13 2020-08-13 한국과학기술연구원 케스페이즈-1 활성 측정용 프로브, 이를 포함하는 염증성 질환 진단용 조성물
EP3863714A4 (en) * 2018-10-09 2022-07-20 University of Virginia Patent Foundation ENDOGENOUS CYTOPLASMATIC ALU-COMPLEMENTARY DNA IN AGE-RELATED MACULAR DEGENERATION
CN110305957B (zh) * 2019-08-22 2022-07-29 中国水产科学研究院淡水渔业研究中心 一种鉴定黄颡鱼脂肪肝程度的试剂盒及其鉴定方法
WO2021041317A1 (en) * 2019-08-23 2021-03-04 University Of Virginia Patent Foundation Ddx17 and nlrc4 targeting for inflammatory diseases
CN115484986A (zh) * 2020-01-06 2022-12-16 海阳制药 用于预防或治疗黄斑变性的含有细胞可渗透的核酸复合物作为活性成分的组合物
US20230355553A1 (en) * 2020-02-11 2023-11-09 University Of Virginia Patent Foundation Compositions and methods for treating and/or preventing ocular disorders
CN111358950A (zh) * 2020-03-20 2020-07-03 厦门大学 Caspase-1及ASC/Caspase-8作为靶点的应用
CN116096378A (zh) * 2020-08-10 2023-05-09 诺华股份有限公司 视网膜变性疾病的治疗
IL301263A (en) 2020-11-18 2023-05-01 Novartis Ag BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF NLRC4-GOF INFLAMMASOMAPATHY
CN115969844B (zh) * 2021-12-28 2024-04-02 首都医科大学附属北京同仁医院 Nox2特异性抑制剂在制备视网膜变性药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
AU2988200A (en) * 1999-02-11 2000-08-29 Trustees Of The University Of Pennsylvania, The Regulation of photoreceptor degeneration
GB9930616D0 (en) * 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US20030186903A1 (en) * 2001-11-23 2003-10-02 Isis Pharmaceuticals Inc. Antisense modulation of MyD88 expression
EP1474444A1 (en) * 2002-01-10 2004-11-10 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. A novel splice variant of myd88 and uses thereof
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US9549895B2 (en) * 2004-04-23 2017-01-24 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
EP1828246A1 (en) * 2004-12-20 2007-09-05 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Myd88 homodimerization inhibitors
US7879992B2 (en) * 2005-01-31 2011-02-01 Isis Pharmaceuticals, Inc. Modification of MyD88 splicing using modified oligonucleotides
EP1746167A1 (en) * 2005-07-20 2007-01-24 Apoxis SA Method for the identification of compounds susceptible to inhibit inflammation
WO2007077042A1 (en) * 2006-01-06 2007-07-12 Topotarget Switzerland Sa New method for the treatment of gout or pseudogout
US20090018094A1 (en) 2006-12-01 2009-01-15 Loma Linda University Medical Center Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration
WO2008150431A1 (en) * 2007-05-29 2008-12-11 Yale University Il- 18 and protein kinase r inhibition for the treatment of copd
US20090227487A1 (en) * 2008-03-05 2009-09-10 Jeremy Pearl Methods for the control of macrophage-associated inflammation
KR20110036966A (ko) * 2008-08-08 2011-04-12 이데라 파마슈티칼즈, 인코포레이티드 안티센스 올리고누클레오티드에 의한 골수 분화 일차 반응 유전자 ８８ （ｍｙｄ８８） 발현의 조절
WO2011133964A2 (en) * 2010-04-23 2011-10-27 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
WO2011153234A2 (en) 2010-06-01 2011-12-08 University Of Kentucky Research Foundation Methods of inhibiting alu rna and therapeutic uses thereof
US20120177632A1 (en) * 2011-01-10 2012-07-12 Shinohara Mari L Methods of optimizing disease treatment

Similar Documents

Publication Publication Date Title
JP2013536015A5 (enExample)
JP2012525415A5 (enExample)
JP2013520405A5 (enExample)
JP2009501797A5 (enExample)
JP2006515351A5 (enExample)
HRP20170531T1 (hr) Novi terapijski pristupi za liječenje alzheimerove bolesti i povezanih poremećaja putem modulacije angiogeneze
MX378707B (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
JP2016508134A5 (enExample)
JP2022550670A5 (enExample)
HRP20120264T1 (hr) Farmaceutski sastavi neuroaktivnog steroida i njihove uporabe
JP2016539125A5 (enExample)
US9415046B2 (en) Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods
JP2015526467A5 (enExample)
WO2015138628A8 (en) Use of aav-expressed m013 protein as an anti-inflammatory therapeutic
JP2013515739A5 (enExample)
WO2007078443A3 (en) Methods of treating unwanted immune response with random copolymers
JP2018530574A5 (enExample)
ES3032941T3 (en) Treatment of hyperinflammatory syndrome
WO2021174024A1 (en) Methods of treating iatrogenic autoimmune colitis
RU2018110647A (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
JP2019511496A5 (enExample)
Emmi et al. Long-term efficacy and safety of anakinra in a patient with Behçet's disease and concomitant tuberculosis infection
RU2014132553A (ru) Фармацевтическая композиция для уменьшения осложнений применения стероидных препаратов при лечении офтальмологических заболеваний
JP2020533302A5 (enExample)
JP2019507775A5 (enExample)